Literature DB >> 7992922

Perturbation of ion channel conductance alters the hypnotic response to the alpha 2-adrenergic agonist dexmedetomidine in the locus coeruleus of the rat.

C Nacif-Coelho1, C Correa-Sales, L L Chang, M Maze.   

Abstract

BACKGROUND: The alpha 2-adrenergic agonists are members of a novel class of hypnotic-anesthetic agents that selectively bind to alpha 2 adrenoceptors in the locus coeruleus (LC) to initiate their pharmacologic action. The postreceptor molecular mechanism of the hypnotic action of alpha 2-adrenergic agonists remains unknown. In this study we addressed the role of conductance through a variety of calcium and potassium ion channels in the hypnotic action of dexmedetomidine in the LC of the rat.
METHODS: Cannulas were inserted stereotactically into the LC of halothane-anesthetized rats (n = 318). After at least 48 h, rats were tested for loss of righting reflex in response to administration of the alpha 2-adrenergic agonist dexmedetomidine at a hypnotic (7.0 micrograms LC) or subhypnotic (3.5 micrograms LC) dose. To establish the mediating role of various species of calcium and potassium ion channels in the hypnotic response, rats were pretreated with the following drugs before the administration of dexmedetomidine LC:S(+)202791 (L-type calcium-channel activator), nifedipine and R(-)202791 (L-type calcium-channel blocker), SNX 111 (N-type calcium-channel blocker), SNX 230 (P-type calcium-channel blocker), quinine (calcium-activated and voltage-gated potassium-channel blocker), charybdotoxin (calcium-activated potassium-channel blocker), dendrotoxin (voltage-gated potassium-channel blocker), or glybenclamide (adenosine triphosphate-sensitive potassium-channel blocker). The drugs were used in doses not causing behavioral effects that could have confounded the interpretation of loss of righting reflex.
RESULTS: SNX 230 and the dihydropyridines nifedipine and R(-)202791 produced loss of righting reflex in the presence of a subhypnotic dose of dexmedetomidine. The hypnotic-enhancing effects of the dihydropyridines could be blocked with S(+)202791, which also diminished loss of righting reflex in response to dexmedetomidine 7.0 micrograms LC. Quinine, dendrotoxin, and charybdotoxin each attenuated the hypnotic response to dexmedetomidine 7.0 micrograms LC. The hypnotic response to dexmedetomidine was not significantly altered by SNX 111 or glybenclamide.
CONCLUSIONS: Inhibition of ion conductance through L- or P-type calcium channels and facilitation of conductance through voltage-gated or calcium-activated potassium channels may be involved in the mechanism of hypnotic action of alpha 2-adrenergic agonists. These changes in ion conductance were capable of producing membrane hyperpolarization and decreasing neuronal excitability. There was no evidence for the involvement of adenosine triphosphate-sensitive potassium channels or N-type calcium channels in the hypnotic response to dexmedetomidine.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7992922     DOI: 10.1097/00000542-199412000-00029

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  22 in total

1.  Substitution of a mutant alpha2a-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo.

Authors:  P P Lakhlani; L B MacMillan; T Z Guo; B A McCool; D M Lovinger; M Maze; L E Limbird
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

Review 2.  General anesthesia and altered states of arousal: a systems neuroscience analysis.

Authors:  Emery N Brown; Patrick L Purdon; Christa J Van Dort
Journal:  Annu Rev Neurosci       Date:  2011       Impact factor: 12.449

Review 3.  Clinical Electroencephalography for Anesthesiologists: Part I: Background and Basic Signatures.

Authors:  Patrick L Purdon; Aaron Sampson; Kara J Pavone; Emery N Brown
Journal:  Anesthesiology       Date:  2015-10       Impact factor: 7.892

4.  Neuroprotection by alpha 2-adrenergic agonists in cerebral ischemia.

Authors:  Yonghua Zhang; Harold K Kimelberg
Journal:  Curr Neuropharmacol       Date:  2005-10       Impact factor: 7.363

5.  Dexmedetomidine Disrupts the Local and Global Efficiencies of Large-scale Brain Networks.

Authors:  Javeria A Hashmi; Marco L Loggia; Sheraz Khan; Lei Gao; Jieun Kim; Vitaly Napadow; Emery N Brown; Oluwaseun Akeju
Journal:  Anesthesiology       Date:  2017-03       Impact factor: 7.892

6.  Sleep and Anesthesia - Common mechanisms of action.

Authors:  Susana Vacas; Philip Kurien; Mervyn Maze
Journal:  Sleep Med Clin       Date:  2013-03

7.  A Pharmacokinetic and Pharmacodynamic Study of Oral Dexmedetomidine.

Authors:  Shubham Chamadia; Juan C Pedemonte; Lauren E Hobbs; Hao Deng; Sarah Nguyen; Luis I Cortinez; Oluwaseun Akeju
Journal:  Anesthesiology       Date:  2020-12-01       Impact factor: 7.892

8.  Antisense technology reveals the alpha2A adrenoceptor to be the subtype mediating the hypnotic response to the highly selective agonist, dexmedetomidine, in the locus coeruleus of the rat.

Authors:  T Mizobe; K Maghsoudi; K Sitwala; G Tianzhi; J Ou; M Maze
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

9.  Oral Dexmedetomidine Promotes Non-rapid Eye Movement Stage 2 Sleep in Humans.

Authors:  Shubham Chamadia; Lauren Hobbs; Sophia Marota; Reine Ibala; Eunice Hahm; Jacob Gitlin; Jennifer Mekonnen; Breanna Ethridge; Katia M Colon; Kimberly S Sheppard; Dara S Manoach; Alan DiBiasio; Sarah Nguyen; Juan C Pedemonte; Oluwaseun Akeju
Journal:  Anesthesiology       Date:  2020-12-01       Impact factor: 7.892

10.  Dexmedetomidine promotes biomimetic non-rapid eye movement stage 3 sleep in humans: A pilot study.

Authors:  Oluwaseun Akeju; Lauren E Hobbs; Lei Gao; Sara M Burns; Kara J Pavone; George S Plummer; Elisa C Walsh; Tim T Houle; Seong-Eun Kim; Matt T Bianchi; Jeffrey M Ellenbogen; Emery N Brown
Journal:  Clin Neurophysiol       Date:  2017-10-20       Impact factor: 3.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.